Keating Financial Advisory Services’s Rigel Pharmaceuticals RIGL Stock Holding History

Keating Financial Advisory Services’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$665	Buy	+17	New	+$524	﹤0.01%	2288

Other funds holding RIGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keating Financial Advisory Services's RIGL Position: Q2 2026 in Review

Keating Financial Advisory Services opened a new position in Rigel Pharmaceuticals (RIGL) in Q2 2026: 17 shares worth $665. The stake represents ﹤0.01% of the portfolio and ranks #2288 among its holdings.

156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

Keating Financial Advisory Services held 17 shares of Rigel Pharmaceuticals worth $665 as of Q2 2026.
Rigel Pharmaceuticals was a new Keating Financial Advisory Services position in Q2 2026.
Rigel Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2288 holding.
156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.